Skip to main content
EyePoint Pharmaceuticals, Inc. logo

EyePoint Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · EYPT ISIN · US74440J1016 LEI · 549300QE1RU34T50MR69 US Manufacturing
Open in API
Filings indexed 1,019 across all filing types
Latest filing 2015-12-04 Director's Dealing
Country US United States of America
Listing US EYPT

About EyePoint Pharmaceuticals, Inc.

https://eyepointpharma.com/

EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for serious retinal diseases. The company leverages its proprietary Durasert E™ technology, a bio-erodible platform for sustained intraocular drug delivery, to create durable therapies. Its lead investigational product, DURAVYU™ (EYP-1901), combines the tyrosine kinase inhibitor vorolanib with the Durasert E™ system for the potential treatment of VEGF-mediated retinal diseases. The company's goal is to improve patient outcomes and reduce treatment burden by providing long-lasting treatments for chronic eye conditions.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2015-12-04 English
FORM 4 SUBMISSION
Director's Dealing
2015-12-04 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated December 3, 2015, reporting the results of the Annual Meeting of Stockholders of pSivida Corp. It details the voting outcomes on various proposals including election of directors, approval of stock option grants, advisory vote on executive compensation, and ratification of the appointment of the independent auditor. The content is focused on the official results from shareholder votes at the annual meeting. The document length is 4341 characters, which is relatively short but contains detailed voting results, not just an announcement of a report. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2015-12-04 English
PRIMARY DOCUMENT
Director's Dealing
2015-12-03 English
Regulatory Filings 2015
Regulatory Filings
2015-12-03 English
Regulatory Filings 2015
Regulatory Filings Classification · 95% confidence The document is a letter from pSivida Corp. to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-3. It is a formal communication related to the registration and effectiveness of a securities filing, not a financial report or detailed disclosure document itself. The document is short (1970 characters) and serves as a procedural request rather than containing financial data or report content. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2015-12-01 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.